Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage

Journal of Cerebral Blood Flow and Metabolism

Volumn 34, Issue 5, 2014, Pages 753-758

  Baron, Jean Claude ^a,b,e   Farid, Karim ^c   Dolan, Eamon ^d   Turc, Guillaume ^b   Marrapu, Siva T ^a   O'Brien, Eoin ^d   Aigbirhio, Franklin I ^a   Fryer, Tim D ^a   Menon, David K ^a   Warburton, Elizabeth A ^d   Hong, Young T ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CENTRE HOSPITALIER SAINTE ANNE   (France)

^c HÔTEL DIEU   (France)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

Author keywords

cerebral amyloid angiopathy; imaging; intracerebral hemorrhage; positron emission tomography

Indexed keywords

PITTSBURGH COMPOUND B;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISTRIBUTION VOLUME; FEMALE; FOLLOW UP; HUMAN; IMAGE PROCESSING; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET SCANNER; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VASCULAR AMYLOIDOSIS;

AGED; AGED, 80 AND OVER; ANILINE COMPOUNDS; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL HEMORRHAGE; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; THIAZOLES;

EID: 84899971919     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2014.43     Document Type: Article

References (40)

1. Charidimou A, Gang Q, Werring DJ. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry 2012; 83: 124-137.
2. Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke 1987; 18: 311-324.
3. Linn J, Halpin A, Demaerel P, Ruhland J, Giese AD, Dichgans M et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 2010; 74: 1346-1350.
4. Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci 2008; 28: 6787-6793.
5. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004; 55: 306-319.
6. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007; 62: 229-234.
7. Greenberg SM, Grabowski T, Gurol ME, Skehan ME, Nandigam RN, Becker JA et al. Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B. Ann Neurol 2008; 64: 587-591.
8. Dierksen GA, Skehan ME, Khan MA, Jeng J, Nandigam RN, Becker JA et al. Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol 2010; 68: 545-548.
9. Gurol ME, Dierksen G, Betensky R, Gidicsin C, Halpin A, Becker A et al. Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy. Neurology 2012; 79: 320-326.
10. 11C-PiB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology 2010; 74: 487-493.
11. Ly JV, Rowe CC, Villemagne VL, Zavala JA, Ma H, O'Keefe G et al. Cerebral betaamyloid detected by Pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activator-related hemorrhage. Ann Neurol 2010; 68: 959-962.
12. Gurol ME, Viswanathan A, Gidicsin C, Hedden T, Martinez-Ramirez S, Dumas A et al. Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study. Ann Neurol advance online publication, 13 December 2012; doi:10.1002/ana.23830 (e-pub ahead of print).
13. Gregoire SM, Chaudhary UJ, Brown MM, Yousry TA, Kallis C, Jager HR et al. The microbleed anatomical rating scale (MARS): reliability of a tool to map brain microbleeds. Neurology 2009; 73: 1759-1766.
14. Yates PA, Sirisriro R, Villemagne VL, Farquharson S, Masters CL, Rowe CC. Cerebral microhemorrhage and brain beta-amyloid in aging and Alzheimer disease. Neurology 2011; 77: 48-54.
15. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 t in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987; 149: 351-356.
16. Vlassenko AG, Mintun MA, Xiong C, Sheline YI, Goate AM, Benzinger TL et al. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol 2011; 70: 857-861.
17. Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 2013; 80: 1784-1791.
18. Chetelat G, La Joie R, Villain N, Perrotin A, de La Sayette V, Eustache F et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin 2013; 2: 356-365.
19. 11C]PiB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-452.
20. Rodrigue KM, Kennedy KM, Devous Sr. MD, Rieck JR, Hebrank AC, Diaz-Arrastia R et al. Beta-amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology 2012; 78: 387-395.
21. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E et al. 18f-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010; 68: 319-329.
22. Landt J, D'Abrera JC, Holland AJ, Aigbirhio FI, Fryer TD, Canales R et al. Using positron emission tomography and carbon 11-labeled Pittsburgh compound B to image brain fibrillar beta-amyloid in adults with Down syndrome: Safety, acceptability, and feasibility. Arch Neurol 2011; 68: 890-896.
23. Kinahan PE RJ. Analytic 3D image reconstruction using all detected events. IEEE Trans Nucl Sci 1989; 36.
24. Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal 2008; 12: 26-41.
25. Laymon CM, Rosario BL, Redfield A, Berginc M, Klunk WE, Mathis CA et al. Comparative evaluation of template-based region sampling for PiB Pet data analysis. Neuroimage. 2010; 51: S219.
26. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15: 273-289.
27. Rosario BL, Weissfeld LA, Laymon CM, Mathis CA, Klunk WE, Berginc MD et al. Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. Neuroimage 2011; 55: 933-941.
28. Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 2003; 54: 343-351.
29. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-840.
30. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab 2005; 25: 1528-1547.
31. Kovari E, Herrmann FR, Hof PR, Bouras C. The relationship between cerebral amyloid angiopathy and cortical microinfarcts in brain ageing and Alzheimer's disease. Neuropathol Appl Neurobiol 2013; 39: 498-509.
32. Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ et al. Visual assessment versus quantitative assessment of 11C-PIB pet and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med 2007; 48: 547-552.
33. Mormino EC, Brandel MG, Madison CM, Rabinovici GD, Marks S, Baker SL et al. Not quite PiB-positive, not quite PiB-negative: slight PiB elevations in elderly normal control subjects are biologically relevant. Neuroimage 2012; 59: 1152-1160.
34. Sojkova J, Driscoll I, Iacono D, Zhou Y, Codispoti KE, Kraut MA et al. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol 2011; 68: 232-240.
35. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011; 69: 181-192.
36. Mathis CA, Kuller LH, Klunk WE, Snitz BE, Price JC, Weissfeld LA et al. In vivo assessment of amyloid-beta deposition in nondemented very elderly subjects. Ann Neurol 2013; 73: 751-761.
37. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65: 1509-1517.
38. Resnick SM, Sojkova J, Zhou Y, An Y, Ye W, Holt DP et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010; 74: 807-815.
39. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-944.
40. Ducharme S, Guiot MC, Nikelski J, Chertkow H. Does a positive Pittsburgh compound B scan in a patient with dementia equal Alzheimer disease? JAMA Neurol 2013; 70: 912-914.